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Abstract
Today, considerable progress in the renal cell carcinoma (RCC) treatment has been made due to development of target­
ed and immunotherapeutic approaches to the RCC treatment, especially in metastasising carcinoma. In the early stages 
of RCC, it is possible to use partial or total surgical nephrectomy, but in metastases development, the range of efficient 
treatment methods is dramatically limited. Appearance of targeted drugs like PD-1 and CTLA-4 receptors and their 
ligands’ inhibitors in clinical practice has significantly increased the total survival rate of patients with renal cell car­
cinoma. Emergence of adoptive cell therapy has opened new possibilities and prospects in RCC treatment. Previously 
activated in vitro cells are used there, which provides antineoplastic activity. For example, it could be antigen-specific 
cytotoxic T-lymphocytes (CTL), lymphokine-activated natural killers (LAK-NK-cells) and tumour-infiltrating lym­
phocytes (TILs). In this review, the authors specified the main molecular markers, associated with RCC; and signalling 
pathways (VEGFR- and EGFR-signalling pathway), which directly take part in carcinogenesis. The paper also looks at 
clinically applicable targeted immune drugs and the principle of their effect on tumorous cells. Besides, modern clinical 
studies of cell drugs have been considered. At the moment, there are a number of variants of targeted and immune drugs 
for the metastatic RCC treatment. Patients have no opportunity to use all the available agents because of their cost and 
toxicity level. For the most efficient treatment of patients with diagnosed metastatic RCC, it is necessarily to carry out 
risk stratification and prognostic factors for the response to treatment.
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Introduction
The problem with oncological diseases throughout the 
world still remains precarious. Annually, 12 million new 
cases of the disease are registered in the world with about 
210,000 of the new cases being renal cell carcinoma 
(RCC). An annual increase of RCC cases in advanced
countries is 1.5 -  5.9%. Renal cancer in Russia ranks 10th 
for the incidence of malignant tumours and only prostate 
cancer has a higher growth rate (Davydov et al. 2011).
Highest incidences of the disease are observed amongst 
the 55-60 age group; RCC is twice as frequent in men 
than in women. Most cases of RCC do not clinically show 
and they are not diagnosed until RCC reaches an ad-
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vanced stage or metastasises. A considerable number of 
RCC cases are diagnosed accidentally. A high metastatic 
potential leads to the fact that metastases are diagnosed in 
25% of patients at the time when the diagnosis was made. 
Fifty percent of patients have locally advanced cancer 
and 25% have localised forms. The disease progression 
and patient’s general condition deterioration are observed 
in 20-40% of cases after nephrectomy. The prognosis of 
the disease course in patients with the metastasising RCC 
is extremely unfavourable: without a specific treatment, 
within a period where the disease progression is 2-4 
months, the average life-span after metastases are detect­
ed is less than 10-13 months (Keane et al. 2007).
As has been proven, smoking tobacco is one of the 
most significant risk factors for development of various 
malignant tumours. The renal tumour emergence risk in 
smokers of both sexes increases by 30% when compared 
with non-smokers. The unfavourable influence of being 
overweight on the renal cancer development probability is 
also confirmed. Obesity leads to an increase of RCC mor­
bidity rate by 20%. RCC emergence is associated with di­
abetes mellitus and the use of diuretics (Chow et al. 2010).
The first classification of RCC was presented in 1826 
and, since then, the approach to this nosology classifica­
tion has repeatedly changed. Today, the renal cell carci­
noma classification singles out four cancer forms, each of 
which has specific genetic changes conditioning different 
clinical process and sensitivity to the treatment undertak­
en. Based on this classification, four forms of renal cell 
carcinoma are distinguished: non-papillary carcinoma or 
clear cell carcinoma (75% of RCC cases), papillary or 
chromophilic cancer (7-14% cases), chromophobic can­
cer (4-10%) and also collecting-duct carcinoma (1-2% 
of RCC cases) (Matveev 2011).
There are a number of renal cell carcinoma treatment 
methods: surgical treatment, ablative method, chemother­
apy, radiotherapy, vessels embolisation, photodynamic 
therapy, immunotherapy and targeted therapy (Matveev 
2011). Surgical treatment has been used for quite some 
time and it is represented mainly by a radical nephrecto­
my and an adrenalectomy. Until recently, a nephrectomy 
was considered the “gold standard”, but it is efficient only 
in patients with an early stage of the localised disease. 
Ultimately, a significant number of the patients develop 
a recurrent tumour. The prognostic factors of RCC recur­
rence or metastasising are: the Karnofsky index score, a 
high level of lactate dehydrogenase (LDH), a low level 
of haemoglobin and high concentration of blood calci­
um. Ablation is an alternative to surgical treatment for 
small renal tumours. Radiotherapy is applied in patients 
with metastatic RCC, who have unresectable sympto­
matic brain or bones affections resistant to the system­
ic therapy. Radiotherapy after a nephrectomy does not 
have any advantages even in patients with metastases in 
lymph nodes or after non-radical surgery (Davydov et al. 
2011). Development of the immunotherapeutic approach 
has reached the level of an important medicinal approach 
in  patients with diffuse renal carcinoma. The following
immunotherapeutic approaches are distinguished: non­
specific immunotherapy with application of cytokines 
(interferones and interleukines) and other biological re­
actions modifiers; immune checkpoint inhibitors therapy, 
adoptive cell immunotherapy by using autolymphocytes, 
lymphokine-activated killers (LAK-cells) and tumour-in­
filtrating lymphocytes (TILs); specific immunotherapy 
(vaccinotherapy, using dendritic cells use) and gene ther­
apy (Matveev 2011).
Kidney cancer targeted therapy
Targeted therapy is a personalised modern approach to 
the medicinal treatment which is formed according to the 
factors, which predict its efficiency. In order to under­
stand the meaning and the mechanism of targeted therapy 
effect, it is necessary to examine molecular markers of re­
nal cell carcinoma. Most of the clear cell carcinomas are 
characterised by a VHL oncosuppresor gene inactivation 
owing to mutations, allelic deletions and/or methylation 
of this gene (Banks et al. 2006). Furthermore, a mutated 
VHL gene underlies Hippel-Lindau disease. Loss or dis­
order of the VHL expression is observed in 50-80% of 
clear cell RCC cases. Probably, the disorder of VHL gene 
activity and intracellular signalling pathways controlled 
by it, is one of the early and key oncogenesis mechanisms 
in RCC and other nosologies. Under physiological condi­
tions, VHL, which is an oncosuppresor (Kim et al. 2010), 
provides intracellular regulation of the HIF-1a (hypox­
ia-induced factor) transcriptional factor level. VHL pro­
tein is an intrinsic part of the ubiquitin ligase complex, by 
which HIF-1a degradation is carried out (Bausch et al. 
2013). The above-mentioned disorders lead to blocking 
or disturbance of the VHL expression. There is an ex­
cess of HIF-1a in a cell, which initiates gene expression 
(VEGF, PDGF, TGF-a and others) induced by hypoxia, 
participating in positive regulation of both cell prolifera­
tion and neoangiogenesis, which allows the cell to tem­
porarily adapt to hypoxia induced by fast and unlimited 
proliferation. It is known, that VEGF plays a central role 
in angiogenesis and this growth factor hyper-expression 
provides new vessels formation (Richard et al. 2013). 
TGF-a is an important factor of autocrine growth stimu­
lation and it can immediately interact with the epithelial 
growth factor receptor (EGFR), which is hyper-expressed 
in 50-90% of kidney tumour cases (Mikami et al. 2015). 
EGFR and VEGF receptors activation initiates one of the 
main mitogenetic signal cascades, namely, Raf / MEK / 
ERK signalling pathway, contributing, in particular, to 
the uncontrolled proliferation of tumour cells.
At the moment, about 15 molecules claiming to be 
diagnostic and prognostic markers of kidney tumours are 
described in literature. Depending on the analysed mate­
rial, the following groups of renal cell carcinoma poten­
tial diagnostic markers are identified: VHL, VEGF, HIF- 
1, survivin, mTOR, carbonic anhydrase 9 (CA9), PTEN, 
tyrosine kinases Akt and S6K, CCL5 and CXCL9, cave-
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olin-1 and others; blood markers (VEGF, CA9) and the 
urine marker NMP-22 (Kovaleva et al. 2014). Almost all 
of the above-mentioned proteins are not specific for this 
pathology. For example, survivin, an inhibiting protein 
of apoptosis, is expressed in all types of cancers, but 
its expression is absent in normal differentiated cells. A 
high quantitative expression of survivin is a bad prog­
nostic marker in RCC (Zamparese et al. 2008). PTEN 
phosphatase is one of a few negative regulators of the 
PBK/AKT/mTOR-signalling pathway, which makes it 
an oncosuppresor. Reduction of PTEN phosphatase ex­
pression is observed in many oncological pathologies 
-  gliomas, meningiomas, melanomas, tumours of the 
kidney, liver, uterus, mammary gland and prostate, - but 
it does not make this marker specific for RCC. Akt and 
S6K tyrosine kinases are included in the mTOR signal­
ling pathway, which regulates different proteins within a 
cell. In assessing the pAkt and pS6K activity, it is pos­
sible to determine the significance of targeted therapy 
with temsirolimus (Cho et al. 2007). Caveolin-1 takes 
part in most of the intracellular signals transduction and 
its expression increase correlates with the unfavourable 
course in oncological pathologies of prostate, oesopha­
gus, lungs, mammary glands as well as RCC (Hehlgans 
and Cordes 2011; Campbell et al. 2008). Under normal 
conditions, CA9 regulates the acid-base balance level 
(рН) in the extracellular matrix by ions binding the H+ 
ion with sodium bicarbonate (Zukov 2013). The CA9 
expression is observed in non-small-cell lung cancer, 
cervical cancer, colon cancer and ovarian cancer, this 
being a negative prognostic factor. CA9 is considered to 
allow a tumour cell to adapt to acidotic conditions which 
develop along with the uncontrolled cells proliferation. 
After that, the tumour is characterised by a more aggres­
sive status. CA9 expression is observed in 90% of clear 
cell RCC cases and, to a lesser extent, it is observed in 
a papillary and chromophobic cancer (Span et al. 2003). 
There are also PBRM1, BAP1 and SETD2 oncosuppre- 
sors, which often mutate in RCC. They are not for direct 
therapeutic purposes, but the signalling pathways regu­
lated by them are being studied for developing new ther­
apeutics (Brugarolas 2013).
Since the discovery of microRNA, a number of mi- 
croRNA markers associated with oncogenesis, including 
in RCC, have been identified. Thus, in clear cell renal car­
cinoma, a high expression of microRNA-28, -185, -27 and 
let-7f-2 has been found. So far, a multitude of microRNA 
associated with RCC subtypes and the course of the dis­
ease have been identified (Heinzelmann et al. 2014). Prob­
ably, a change of expression in one or another microRNA 
associated with RCC by specific inhibitors can have a pos­
itive therapeutic effect.
As VHL inactivation is a fundamental event in RCC, 
these tumours are characterised by intensive growth of 
vessels. Due to that, in the first- and second-line treatments 
in metastatic RCC, tyrosine kinases inhibitors directed at 
the whole VEGFR-signalling pathway are used. Such in­
hibitors are sorafenib, sunitinib, pazopanib, axitinib, len-
vatinib and cabozantinib. Furthermore, combinations of 
lenvatinib and everolimus or bevacizumab (anti-VEGF 
antibodies) and interferon alpha are used (Escudier et al. 
2007; Motzer et al. 2015). Each drug depresses VEGFR 
(VEGFR-1, VEGFR-2, VEGFR-3) to varying degrees. 
Differences in efficiency can be explained both by differ­
ent activity and toxicity of each drug and by an individual 
response of each patient’s organism. Taking into account 
the mTOR importance in RCC progression, mTOR inhibi­
tors -  everolimus and temsirolimus, -  are used in the first- 
and second-line therapies in patients with a low risk level 
of recurrence (Motzer et al. 2008, Hsieh et al. 2017).
Modern strategies of advanced or metastatic RCC 
treatment include VEGFR and mTOR inhibitors as the 
first-line therapy (Choueiri et al. 2016). In the AXIS 
research, axitinib, which is a powerful inhibitor for all 
three VEGF receptors, increases the median survivabil­
ity without progression in comparison with sorafenib (a 
multikinase inhibitor; 8.3 months against 5.7 months) in 
patients previously taking sunitinib (a multikinase inhib­
itor), bevacizumab (antibody to VEGF) with interferon 
alpha, temsirolimus (an mTOR inhibitor) and cytokines 
(Motzer et al. 2013). In the METEOR research, cabozan- 
tinib exceeds everolimus both in the median survivability 
rates (7.4 months against 3.8 months) and in the aver­
age total survivability rates (21.4 months against 16.5 
months) (Choueiri et al. 2016). In phase 2 of CABOSUN 
research, cabozantinib (antibody to VEGFR) was com­
pared with sunitinib in the first-line treatment of patients 
with RCC. The therapy with cabozantinib increases the 
median survivability (8.2 months against 5.6 months) 
(Motzer et al. 2013). Pazopanib is another kinase inhib­
itor demonstrating efficiency in the first-line treatment. 
In comparison with the placebo, pazopanib considerably 
prolongs recurrence-free survivability. When comparing 
pazopanib with sunitinib, a similar efficiency is observed, 
but pazopanib is better tolerated by a patient’s organism 
(Motzer et al. 2014).
Combining the targeted drugs can become an alter­
native strategy to developing more powerful drugs. This 
approach is based on the fact that VEGFR inhibition is 
not always efficient. This is due to the fact that tumours 
“use” signalling pathways not only those connected with 
VEGFR but also those running in parallel with VEGFR 
signalling pathways. These pathways also stimulate on­
cogenic and metastatic signals, which develop resistance 
to some or other targeted drugs. The combination of len- 
vatinib (antibody to VGFR) and everolimus (antibody to 
mTOR) can be considered a successful example of such a 
strategy. Such a therapy prolongs the median survivabil­
ity in comparison with everolimus (14.6 months and 5.5 
months). On the other hand, the combination therapy has 
a strong toxic effect (Motzer et al. 2015). Combination 
therapy is being quite actively developed. It is known that 
CD105 (endolgin) is a strong angiogeneses factor taking 
part in VEGFR inhibition. The combination of a mono­
clonal antibody to CD105 (TRC105) and axitinib or bev- 
acizumab is clinically efficient in the first phase of the
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research. Currently this combination is being tested in the 
second phase of clinical studies in patients with advanced 
and metastatic RCC (Choueiri et al. 2014). Dalantercept, 
inhibiting ALK-1 and being a receptor playing a crucial 
role in pathological angiogenesis, is actively studied in 
connection with axitinib in advanced RCC.
Even though targeted drugs affect the key elements 
of oncogenesis, currently available drugs do not have 
an equally positive effect for each patient. Different re­
sponse of patients is conditioned by individual biological 
factors. The introduction of a new generation of sequenc­
ing can help to discover genomic and/or transcriptomic 
variations, which can predict the degree of positive re­
sponse to a specific therapy. This approach can lead to 
the individual therapy after diagnosing metastatic RCC. 
A retrospective analysis of patients’ tissues revealed the 
expected predictive markers of response to the treat­
ment. In a sample of 79 patients receiving mTOR, in­
hibitors sequencing showed that mutations in mTOR, 
TSC1 or TSC2 occurred more often in patients respond­
ing to therapy (Kwiatkowski et al. 2016). In a clinical 
study comparing everolimus with sunitinib in clear cell 
RCC, it was found that mutations in the PBRM1 locus 
were related to longer survivability in patients receiving 
everolimus. At the same time, this mutation does not af­
fect a response in patients receiving sunitinib (Hsieh et 
al. 2017). These biomarkers can be useful when select­
ing personalised drugs.
At the moment, there are many variants of targeted 
drugs for the metastatic RCC treatment. Patients have no 
opportunity to use all of the available drugs because of 
their cost and toxicity level. For the most efficient treat­
ment of patients with diagnosed metastatic RCC, it is nec­
essary to carry out risk stratification and identify prognos­
tic factors of a response to treatment. Taking into account 
the range of therapeutic possibilities available to patients, 
defining a treatment strategy should be undertaken based 
on individual characteristics, so that the therapy selection 
should become more personalised.
Kidney cancer immunotherapy
Immunotherapy is often perceived as a new method for 
the treatment of oncological diseases. However in the late 
19th century, surgeon William Coley administered an in­
jection of inactivated bacteria into a sarcoma’s inoperable 
tissue, which subsequently led to the tumour reduction. 
Later, he developed a mixed bacterial vaccine and achie­
ved long remission in some patients with sarcoma and 
other types of tumours (Kienle 2012). Later, it was de­
termined that cancerous cells expressed tumour antigens 
capable of stimulating cell and/or humoural immunity. 
These antigens’ expression paves the way for treatment 
of oncological diseases using methods of immunothera­
py (Kit et al. 2016). Peptides derived from tumour anti­
gens are represented by class I and class II epitopes of the 
major histocompatibility complex (MHC) and they can
stimulate CD8+ and CD4+ Т-cells. Binding a Т-cell re­
ceptor (TCR) with the MHC peptide requires additional 
co-stimulatory signals. Binding activates signalling path­
ways leading to the secretion of pro-inflammatory cytoki­
nes. The binding amplitude and quality are regulated by 
a balance between co-stimulatory and inhibitory signals 
-  “immune checkpoints” (Pardoll 2012).
The human immune system has an inherent ability to 
adapt to different pathologies like infections or cancer 
creating a varied repertoire of effector Т-cells. Cancerous 
cells can increase the expression of apoptosis inhibitors 
and expression on the cell surface of molecules killing cy­
totoxic Т-cells. Tumours are capable of releasing factors 
inhibiting inborn and acquired immunity and they also can 
accumulate regulatory cells for creating the immuno-sup- 
pressing microenvironment. All of these factors prevent 
the natural human immunity from fighting a  tumour.
RCC has long been recognised as a malignant neo­
plasm, which can be treated with stimulating the immune 
system by cytokines: recombinant interferon alpha and 
high concentration of interleukin 2 (IL 2) (Klapper et al.
2008) . Interferon and high concentration of IL 2 have 
been used to treat metastatic RCC since the 1990s, be­
fore the use of sunitinib (McDermott et al. 2005). The 
high toxicity of IL 2, however, often limits its use, despite 
cases of complete remission in some patients (Hutson 
et al. 2016). Patients taking interferon alpha have prob­
lems with depression and thrombocytopenia (McDermott
2009) . Introduction of new methods of treatment has led 
to the lower frequency of cytokines use.
To prevent an autoimmune response, the organism has 
immune checkpoints: T-lymphocyte-associated protein-4 
(CTLA-4) and ligand 1 of programmed cell death (PD-L1). 
CTLA-4 is situated on the T-cell surface and counteracts 
a CD28 co-stimulatory receptor. CTLA-4 and CD28 bind 
with similar ligands CD80 and CD86, but CTLA-4 has the 
higher affinity for these ligands and due to this makes a 
strong competition to CD28. Moreover, CTLA-4 can se­
quester CD80 and CD86 from CD28, which also leads to 
suppressing the Т-cell response (Pardoll 2012). PD-1 is a 
transmembrane protein, which is more widely expressed 
than CTLA-4 and it is found on T-cells, B-cells and NK- 
cells. PD-1 binds with both ligands PD-L1 and PD-L2, 
which are usually expressed on the surface of tumour cells. 
The interaction between PD-1 and ligands inhibits kinases 
activating Т-cells, induces anergy amongst antigen-spe­
cific Т-cells and converts effector Т-cells into regulatory 
T-cells (Amarnath et al. 2011). Cancerous cells use these 
factors for masking from cellular immunity (Schreiber et 
al. 2011). Blocking this interaction demonstrated an im­
pressive tumour remission in different types of solid tu­
mours including RCC, melanoma, non-small-cell lung 
cancer and colorectal cancer (Brahmer et al. 2010).
PD-L1 and CTLA-4 inhibition promotes Т-cells activa­
tion. Subsequently, it was discovered that the use of PD- 
L1 and CTLA-4 blockers was efficient against malignant 
tumours and, in doing so, they have a lower toxicity level 
than cytokines (interferon alpha and interleukin-2). These
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rates led to the creation of many antineoplastic immune 
agents, such as anti-CTLA-4-antibodies (ipilimumab, 
tremelimumab), anti-PD-1-antibodies (nivolumab, pem- 
brolizumab) and anti-PD-L1-antibodies (atezolizumab, 
avelumab, durvalumab). These drugs have been approved 
for treatment of melanoma, lung cancer and bladder 
cancer (Balar 2017). Currently new CTLA-4 inhibitors 
(tremelimumab) and PD-1 inhibitors (pidilizumab) are 
being developed for RCC treatment (Drake et al. 2014).
Nivolumab is the first PD-1 inhibitor approved by 
the FDA for mRCC treatment after therapy with VEG- 
FR inhibitor. In the CheckMate research, patients taking 
VEGFR inhibitors received nivolumab or everolimus (an 
mTOR inhibitor). Research shows the difference in total 
survivability in favour of nivolumab (25 months against 
19.6 months, p=0.002). However, the response frequency 
was only 25% and most of the patients receiving therapy 
did not respond to treatment (Motzer et al. 2015).
Despite the beneficial effects and low toxicity of new 
inhibitors, these agents did not show a sufficient num­
ber of complete remission cases (Escudier et al. 2017). 
Tumours with a higher mutation load are characterised 
by a good reaction and a longer clinical response (Voron 
2015). The immunotherapy effect can be reinforced by 
inhibiting the secondary immune checkpoints. This idea 
led to development of a series of new inhibitors and new 
targets: TIM 3, VISTA, LAG-3, IDO-1, KIR, B40, GITR, 
OX40L, CD137 and ICOS. All these targets, such as 
molecules, antigenes, receptors etc., take part in immune 
checkpoints and are under active development for treat­
ing oncological pathologies including metastatic RCC 
(Dempke et al. 2017).
As well as with targeted drugs, combining immune 
checkpoint inhibitors can reinforce the positive effect 
of the therapy. In phase 1 of the research, the combina­
tion of ipilimumab (anti-CTLA-4) and nivolumab (an- 
ti-PD-1) increased the positive response to the treatment 
in metastatic RCC (Hammers et al. 2017). Taking into 
account positive effects of immune checkpoint inhibi­
tors in RCC treatment, it is necessary to identify patients 
susceptible to the therapy with these agents. It was con­
sidered that PD-L1 expression in tumours and immune 
cells could be considered a prognostic factor, but studies 
showed that a low expression or no expression of PD-L1
did not guarantee the absence of a response to the ther­
apy with PD-1 or PD-L1 inhibitors (Callea et al. 2015). 
Combination of immunotherapy with targeted drugs, 
such as VEGFR inhibitors, is currently being tested (Vo- 
ron et al. 2015).
Toxic effects of proangiogenic signalling pathways in­
hibitors differ from toxic effects of immune checkpoint 
inhibitors in RCC treatment. VEGFR inhibitors are asso­
ciated with hypertension, hand-foot syndrome and other 
side effects (Motzer et al. 2013). Immune checkpoint in­
hibitors are relatively non-toxic, but they can induce an 
autoimmune response, which can negatively affect the 
organism’s endocrine, gastrointestinal, respiratory sys­
tems and skin (Larkin et al. 2015). Another widespread 
and early toxicity form is dermatological disorders, but 
they are easily treated with corticosteroids. Diarrhoea and 
colitis are also common side effects, which are more often 
encountered in anti-CTLA-4-antibodies therapy. Hepato- 
toxicity and endocrinopathy are possible (Liu et al. 2017). 
Different inhibitors in RCC, which are being clinically 
tested, are described in Table 1.
The significance of immunotherapy in treating RCC 
has dramatically increased since the beginning of this 
century. Previously, therapy with IL-2 and IFN-a cyto- 
kinins was incorporated as a basis for mRCC immuno­
therapy. However, the effect was largely negative, con­
sidering all toxic effects when using cytokines. Immune 
checkpoint inhibitors became an important element in 
RCC treatment. These agents are gradually being intro­
duced into treatment of mRCC and other cancer types, 
such as melanoma, non-small-cell lung cancer, Hodg­
kin’s disease and head and neck cancer. Nivolumab is 
approved and available for patients with mRCC. PD-1 
inhibitors demonstrate long remissions and tolerable tox­
icity profile. To optimise a treatment strategy, it is also 
necessary to determine and use predictive biomarkers of 
response to the treatment.
Kidney cancer cell therapy
Different vaccines for RCC treatment are currently 
being actively developed. Vaccines are used for trea­
ting a primary tumour, but not for preventing an onco-
Table 1. Immune drugs in RCC are currently being clinically tested (Liu et al. 2017).
Drug Target




Source of information 
or NCT
Nivolumab CTLA-4 4 2 NCT02596035
Atezolizumab PD-L1 3 1 NCT02420821
Avelumab PD-L1 3 1 NCT02684006
Nivolumab + Ipilimumab PD-1
CTLA-4
3 1 NCT02231749
Ipilimumab CTLA-4 2 1 NCT00057889
Pembrolizumab PD-1 1/2 1/2 NCT02014636
Pembrolizumab + Ipilimumab PD-1
CTLA-4
1 2 NCT02089685
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logical disease. Clinical trials are conducted to assess 
the effectiveness of different vaccines, but none has so 
far demonstrated an increase in the survivability rate. 
High immunogenicity of cancerous antigens provides 
the possibility for a wide range of studies for these 
agents aimed at antineoplastic vaccination (Vodolazhs- 
kii et al. 2017).
AGS-003 is a vaccine based on dendritic cells (DCs), 
where DCs are electroporated by amplificated tumour 
mRNA and synthetic CD40L-RNA. It is considered that 
CD40L expression on DC surfaces promotes CD8-pos- 
itive Т-cells recruitment through co-stimulatory signals 
induction (IL-2). The phase 2 research included 21 pa­
tients with an intermediate or clear prognostic category 
of metastasis risk. The efficiency of combining AGS-003 
with sunitinib (a growth factor receptors inhibitor) was 
assessed. Nine patients had a partial response, in four pa­
tients the disease was stabilised, and eight patients had 
the disease progression. Treatment with this combina­
tion provided the average survivability without progres­
sion for 11.2 months and the total survivability for 30.2 
months with 5 patients having a survivability rate over 
5 years. Based on these results, the phase 3 research, in 
which patients with mRCC are being treated with sunitin- 
ib or a combination of sunitinib with AGS-003, is being 
conducted (ClinicalTrials.gov 2017).
IMA-901 is a vaccine consisting of peptides associated 
with tumours and expressed in cancer tissue (Rini et al. 
2016). In the phase 2 research of combining the cyclo­
phosphamide (B-cells inhibitor), IMA-901 and GM-CSF, 
it was demonstrated that this combination stabilised dis­
ease development in 31% of patients receiving cytokines 
therapy after 6 months and in 14% of patients previously 
receiving tyrosine kinases inhibitors (Walter 2012). In 
separate research of phase 3 involving 339 patients, the 
efficiency of combination therapy with sunitinib, IMA- 
901 and GM-CSF was assessed. Addition of IMA-901 to 
sunitinib did not show any effects (Rini et al. 2015).
TroVax is a therapeutic vaccine aimed at a carcinoem- 
bryonic antigen 5T4. This tumour-associated antigen 
is hyper-expressed in most RCC cases (Griffiths et al. 
2005). In phase 3 of TRIST research, TroVax in combi­
nation with interferon alpha, interleukin 2 or sunitinib, 
as the first-line treatment, demonstrated a significant in­
crease in the total response concerning the therapy with­
out TroVax (Amato et al. 2010).
Another type of vaccines is the lysate of autologous 
tumour cells. Based on the lysate of autologous tumour 
cells, this vaccine stimulates antigen-presenting cells 
(APC) which, in turn, promote the cytotoxic Т-lympho­
cytes response to the antigens expressed on RCC cells 
(Wittke et al. 2016). The vaccine based on the lysate of 
autologous tumour cells prolonged the survivability with­
out progression in the phase 3 clinical research in patients 
with RCC (May et al. 2010).
There are a few perspective trials of vaccines based 
on dendritic cells. For example, there is a trial of a DC- 
based vaccine being conducted, where autologous DCs 
are loaded with a hybrid gene structure of GM-CSF and 
carbonic anhydrase IX (ClinicalTrials.gov 2017). A trial 
of pidilizumab (anti-PD-1) and activated by RCC cells on 
DCs is also underway (ClinicalTrials.gov 2017). There 
has also been a study using DCs in combination with 
LAK-cells in mRCC (ClinicalTrials.gov 2017).
An encouraging immunotherapy method is adoptive 
cell therapy which uses cells previously activated in vit­
ro and which provides antineoplastic activity. For exam­
ple, it could be antigen-specific cytotoxic T-lymphocytes 
(CTL), lymphokine-activated natural killers (LAK-NK- 
cells) or tumour-infiltrating lymphocytes (TILs) (Per- 
ica et al. 2015; Tang et al. 2013). A series of adoptive 
cell therapy studies in patients with mRCC showed that 
the median survivability level was 10.2 months and a 
five-year survival rate was observed in 15% of patients 
(Combe at al. 2015). In any case, the significance of the 
cell therapy in mRCC is still not clear.
Conclusions
New ideas of cancer development have led to the creation 
of new immunomodulatory agents. The ways of treating 
mRCC develop quite fast for new target agents with diffe­
rent treatment regimens being developed, which, in turn, 
are being optimised. The results of recent clinical trials 
of immunotherapeutic agents prove that immunotherapy, 
such as the monotherapy or in combination with other 
agents, can provide a long-term response and significant 
total increase in survivability.
As immunotherapy use is becoming increasingly wi­
despread in oncology, a number of related problems 
and questions arise. For example, important factors are 
long-term side effects and mechanisms for developing re­
sistance to these drugs in different tumours (Khunger et 
al. 2017). Further studies and experience in this area will 
allow to better determine strategies for using immunothe- 
rapeutic agents not only in RCC, but also in many other 
malignant neoplasms.
There is some preclinical evidence for combining im­
munotherapy with anti-VEGF inhibitors. Furthermore, 
development and clinical implementation of prognostic 
biomarkers can be crucial for applying immunotherapy. 
Preliminary studies, especially of PD-L1 expression by 
an immunohistochemical test in tumour cells, do not pre­
dict a tumour response to immune drugs.
Using immunotherapy in RCC has great potential after 
the use of inhibitors for the immune checkpoint has been 
started. In the future, immunotherapy by itself or together 
with other treatment methods, is likely to cause a paradigm 
shift in the clinical treatment of patients with mRCC.
Research Result: Pharmacology and Clinical Pharmacology 4(1): 17-25 23
References
■ Davydov MI, Aksel EM (2011) Morbidity of Malignant Neoplasms 
Among the Population in Russia and the CIS Countries in 2008. 
Bulletin of the RCRC by NN Blokhin. [Vestnik RONc im. NN Blo- 
hina RAMN] 22(3): 54-92. [in Russian]
■ Keane T, Gillatt D, Evans CP, Tubaro A (2007) Current and Future 
Trends in the Treatment of Renal Cancer. European Urology Supple­
ments 6(3): 374-384. https://doi.org/10.1016/j.eursup.2006.12.006 
[ScienceDirect]
■ Chow WH, Dong LM, Devesa SS (2010) Epidemiology and Risk 
Factors for Kidney Cancer. Nature Reviews Urology 7(5): 245-257. 
https://doi.org/10.1038/nrurol.2010.46 [PMC].
■ Matveev BP (Ed.) (2011) Clinical Oncourology. Moscow: ABV- 
Press, 11-226 p. (Russian)
■ Banks RE, Tirukonda P, Taylor C, Hornigold N (2006) Genetic and 
Epigenetic Analysis of von Hippel-Lindau (VHL) Gene Alterations 
and Relationship with Clinical Variables in Sporadic Renal Cancer. 
Cancer Research 66(4): 2000-2011. https://doi.org/10.1158/0008- 
5472.CAN-05-3074 [PubMed] [Full text]
■ Kim JJ, Rini BI, Hansel DE (2010) Von Hippel-Lindau Syndrome. 
Diseases of DNA Repair. Springer New Yorkp 228-249 p. https:// 
doi.org/10.1002/(SICI)1097-0142(19991201)86 [Springer Link]
■ Bausch B, Jilq С, Glasker S, Vortmeyer A, et al. (2013) Renal Can­
cer in von Hippel-Lindau Disease and Related Syndromes. Nature 
Reviews Nephrology 9(9): 529-538. https://doi.org/10.1038/nr- 
neph.2013.144 [PubMed]
■ Richard S, Gardie B, Couve S, Gad S (2013) Von Hippel-Lindau: 
How a Rare Disease Illuminates Cancer Biology. Seminars in Can­
cer Biology. Academic Press 23(1): 26-37. https://doi.org/10.1016/j. 
semcancer.2012.05.005 [PubMed]
■ Mikami S, Mizuno R, Kosaka T, Saya H, et al. (2015) Expression of 
TNF-a and CD44 is Implicated in Poor Prognosis, Cancer Cell Inva­
sion, Metastasis and Resistance to the Sunitinib Treatment in Clear 
Cell Renal Cell Carcinomas. International Journal of Cancer 136(7): 
1504-1514. https://doi.org/10.1002/ijc.29137 [Onlinelibrary]
■ Kovaleva OV, Nazarova OR, Mateeva VB, et al. (2014) Molecular 
Features of Renal Cell Carcinoma: Early Diagnostics and Therapy 
Prospect. Progress of Molecular Oncology. [Uspekhi molekulyarnoj 
onkologii] 2: 36-46. [in Russian]
■ Zamparese R, Pannone G, Santoro A, Muzio LL, et al. (2008) 
Survivin Expression in Renal Cell Carcinoma. Cancer Investiga­
tion 26(9): 929-935. https://doi.org/10.1080/07357900802017553 
[Tandfonline]
■ Cho D, Signoretti S, Regan M, Seeley A, et al. (2007) Potential His­
tologic and Molecular Predictors of Response to Temsirolimus in Pa­
tients with Advanced Renal Cell Carcinoma. Clinical Genitourinary 
Cancer 5(6): 379-385. https://doi.org/10.3816/CGC.2007.n.020 
[ScienceDirect]
■ Hehlgans S, Cordes N (2011) Caveolin-1: an Essential Modulator of 
Cancer Cell Radio-and Chemoresistance. American Journal of Can­
cer Research 1(4): 521. [PubMed] [Full text]
■ Zukov RA (2013) Renal Cell Carcinoma Treatment: Opportunities, 
Problems, Prospects. Siberian Medical Review. [Sibirskoe medicin- 
skoe obozrenie] 3: 81. [in Russian]
■ Campbell L, Jasani B, Edwards K, Gumbleton M, et al. (2008) Com­
bined Expression of Caveolin-1 and an Activated AKT/mTOR Path­
way Predicts Reduced Disease-free Survival in Clinically Confined 
Renal Cell Carcinoma. British Journal of Cancer 98(5): 931. https:// 
doi.org/10.1038/sj.bjc.6604243 [PubMed] [Full text]
■ Span PN, Bussink J, Manders P, Beex LV, et al. (2003) Carbonic An- 
hydrase-9 Expression Levels and Prognosis in Human Breast Can­
cer: Association with Treatment Outcome. British Journal of Cancer 
89(2): 271. https://doi.org/10.1038/sj.bjc.6601122 [PubMed] [Full 
text]
■ Brugarolas J (2013) PBRM1 and BAP1 as Novel Targets for Renal 
Cell Carcinoma. Cancer Journal 19(4): 324. https://doi.org/10.1097/ 
PPO.0b013e3182a102d1 [PubMed] [Full text]
■ Heinzelmann J, Unrein A, Wickmann U, Baumgart S, et al. (2014) 
MicroRNAs with Prognostic Potential for Metastasis in Clear Cell 
Renal Cell Carcinoma: a Comparison of Primary Tumors and Dis­
tant Metastases. Annals of Surgical Oncology 21(3): 1046-1054. 
https://doi.org/10.1245/s10434-013-3361-3 [Springer Link]
■ Escudier B, Eisen T, Stadler W, Szczylik C, et al. (2007) Sorafenib 
in Advanced Clear-cell Renal-cell Carcinoma. New England Jour­
nal of Medicine 356(2): 125-134. https://doi.org/10.1056/NEJ- 
Moa060655 [New England Journal of Medicine]
■ Motzer RJ, Huston TE, Glen H, Michaelson D, et al. (2015) Lenvati- 
nib, Everolimus, and the Combination in Patients with Metastatic 
Renal Cell Carcinoma: a Randomised, Phase 2, Open-label, Mul­
ticentre trial. The Lancet Oncology 16(15): 1473-1482. https://doi. 
org/10.1016/S1470-2045(15)00290-9 [ScienceDirect]
■ Motzer RJ, Escudier B, Oudard S, Huston TE, et al. (2008) Effi­
cacy of Everolimus in Advanced Renal Cell Carcinoma: a Dou­
ble-blind, Randomised, Placebo-controlled Phase III Trial. The 
Lancet 372(9637): 449^56. https://doi.org/10.1016/S0140-
6736(08)61039-9 [ScienceDirect]
■ Hsieh JJ, Purde MP, Siqnoretti S, Swanton C, et al. (2017) Renal 
Cell Carcinoma. Nature Reviews. Disease Primers 3: 17009. https:// 
doi.org/10.1038/nrdp.2017.9 [PubMed]
■ Choueiri TK, Escudier B, Powles T, Tannir NM, et al. (2016) 
Cabozantinib Versus Everolimus in Advanced Renal Cell Carci­
noma (METEOR): Final Results From a Randomised, Open-label, 
Phase 3 Trial. The Lancet Oncology 17(7): 917-927. https://doi. 
org/10.1016/S1470-2045(16)30107-3 [ScienceDirect]
■ Motzer RJ, Escudier B, Hutson PTE, Michaelson D, et al. (2013) 
Axitinib Versus Sorafenib as Second-line Treatment for Advanced 
Renal Cell Carcinoma: Overall Survival Analysis and Updated 
Results From a Randomised Phase 3 Trial. The Lancet Oncology 
14(6): 552-562. https://doi.org/10.1016/S1470-2045(13)70093-7 
[ScienceDirect]
■ Motzer RJ, Huston T, McCann L, Choueiri TK (2014) Overall Sur­
vival in Renal-cell Carcinoma with Pazopanib Versus Sunitinib. 
New England Journal of Medicine 370(18): 1769-1770. https://doi. 
org/10.1056/NEJMc1400731 [New England Journal of Medicine]
■ Choueiri TK, Michaelson MD, Posadas EM, Sonpavde G, et al. 
(2014) A Phase 1b Dose-escalation Study of TRC105 (anti-endoglin 
antibody) in Combination with Axitinib in Patients with Metastatic
24 Pushkin AA et al.: Renal cell carcinoma drug and cell therapy: today and tomorrow
Renal Cell Carcinoma (mRCC). Journal of Clinical Oncology 33(7): 
426. https://doi.Org/0.1200 / jco.2015.33.7_suppl.426 [JCO]
■ Kwiatkowski DJ, Choueiri TK, Fay AP, Rini BI, et al. (2016) Muta­
tions in TSC1, TSC2, and MTOR are Associated with Response to 
Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clinical 
Cancer Research 22(10): 2445-2452. https://doi.org/10.1158/1078- 
0432.CCR-15-2631 [PubMed] [Full Text]
■ Hsieh JJ, Chen D, Wang PI, Marker M, et al. (2017) Genomic Bi­
omarkers of a Randomized Trial Comparing First-line Everolimus 
and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. 
European Urology 71(3): 405-414. https://doi.org/10.1016/j.euru- 
ro.2016.10.007 [ScinceDirect]
■ Kienle GS (2012) Fever in Cancer Treatment: Coley’s Therapy and 
Epidemiologic Observations. Global Advances in Health and Medi­
cine 1(1): 92-100. https://doi.org/10.7453/gahmj.2012.1.1.016 [Pu- 
bMed] [Full Text]
■ Kit OI, Vodolazhskii DI, Mogushkova KhA, Pushkin AA, et al. 
(2016) Mechanisms of Regulating Expression of Cancerous Testic­
ular Antigens. Modern Problems of Science and Education. [Sovre- 
mennye problemy nauki i obrazovaniya] 5: 134-134. [in Russian]
■ Pardoll DM (2012) The Blockade of Immune Checkpoints in Can­
cer Immunotherapy. Nature Reviews. Cancer 12(4): 252. https://doi. 
org/10.1038/nrc3239 [PMC]
■ Klapper JA, Downey SG, Smith FO, Yang JC, et al. (2008) High- 
dose Interleukin-2 for the Treatment of Metastatic Renal Cell Carci­
noma. Cancer 113(2): 293-301. https://doi.org/10.1002/cncr.23552 
[Online Library]
■ McDermott DF, Regan MM, Clark JI, Flaherty LE, et al. (2005) 
Randomized Phase III Trial of High-dose Interleukin-2 Versus Sub­
cutaneous Interleukin-2 and Interferon in Patients with Metastatic 
Renal Cell Carcinoma. Journal of Clinical Oncology 23(1): 133­
141. https://doi.org/10.1200/JCO.2005.03.206 [JCO]
■ Hutson TE, Thoreson GR, Fiqlin RA, Rini BI, et al. (2016) The 
Evolution of Systemic Therapy in Metastatic Renal Cell Carcino­
ma. American Society of Clinical Oncology Educational Book 35: 
113-117. https://doi.org/10.14694/EDBK_158892 [PubMed]
■ McDermott DF (2009) Immunotherapy of Metastatic Renal Cell 
Carcinoma. Cancer 115(S10): 2298-2305. https://doi.org/10.1002/ 
cncr.24236 [Online Library]
■ Amarnath S, Mangus CW, Wang JCM, Wei F, et al. (2011) The 
PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T 
Cells. Science Translational Medicine 3(111): 111. https://doi. 
org/10.1126/scitranslmed.3003130 [Science translational medicine]
■ Schreiber RD, Old LJ, Smyth MJ (2011) Cancer Immunoediting: 
Integrating Immunity’s Roles in Cancer Suppression and Promo­
tion. Science 331(6024): 1565-1570. https://doi.org/10.1126/sci- 
ence.1203486 [Science]
■ Brahmer JR, Drake CG, Wollner I, Powderly JD, et al. (2010) Phase I 
Study of Single-agent Anti-programmed Death-1 (MDX-1106) in Re­
fractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, 
and Immunologic Correlates. Journal of Clinical Oncology 28(19): 
3167-3175. https://doi.org/10.1200/JCO.2009.26.7609 [JCO]
■ Balar AV, Galsky MD, Rosenberg JE, Powles T, et al. (2017) 
Atezolizumab as First-line Treatment in Cisplatin-ineligible Patients 
with Locally Advanced and Metastatic Urothelial Carcinoma: a Sin­
gle-arm, Multicentre, Phase 2 Trial. The Lancet 389(10064): 67-76. 
https://doi.org/10.1016/S0140-6736(16)32455-2 [ScienceDirect]
■ Drake CG, Lipson EJ, Brahmer JR (2014) Breathing New Life into 
Immunotherapy: Review of Melanoma, Lung and Kidney Can­
cer. Nature Reviews Clinical Oncology 11(1): 24-37. https://doi. 
org/10.1038/nrclinonc.2013.208 [Full text]
■ Motzer RJ, Escudier B, McDermott DF, George S, et al. (2015) 
Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma. 
New England Journal of Medicine 373(19): 1803-1813. https://doi. 
org/10.1056/NEJMoa1510665 [New England Journal of Medicine]
■ Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, et al. 
(2017) Treatment Beyond Progression in Patients with Advanced 
Renal Cell Carcinoma Treated with Nivolumab in CheckMate 
025. European Urology 72: 2017. https://doi.org/10.1016Zj.euru- 
ro.2017.03.037 [ScienceDirect]
■ Voron T, Colussi O, Marcheteau E, Pernot S, et al. (2015) VEGF-A 
Modulates Expression of Inhibitory Checkpoints on CD8+ T Cells 
in Tumors. Journal of Experimental Medicine 212(2): 139-148. 
https://doi.org/10.1084/jem.20140559 [JEM]
■ Dempke WCM, Fenchel K, Uciechowski P, Dale SP (2017) Sec- 
ond-and Third-generation Drugs for Immuno-oncology Treatment
— The More the Better? European Journal of Cancer 74: 55-72. 
https://doi.org/10.1016/j.ejca.2017.01.001 [ScienceDirect]
■ Hammers HJ, Plimack ER, Infante JR, Rini BI, et al. (2017) Safety 
and Efficacy of Nivolumab in Combination with Ipilimumab in Met­
astatic Renal Cell Carcinoma: The CheckMate 016 Study. Journal of 
Clinical Oncology. https://doi.org/10.1200/JCO.2016.72.1985 [JCO]
■ Callea M, Albiges L, Gupta M, Cheng SC, et al. (2015) Differential 
Expression of PD-L1 Between Primary and Metastatic Sites in Clear­
cell Renal Cell Carcinoma. Cancer Immunology Research 3(10): 
1158-1164. https://doi.org/10.1158/2326-6066.CIR-15-0043 [PMC]
■ Larkin J, Sileni VC, Gonzales R, Grob JJ, et al. (2015) Combined 
Nivolumab and Ipilimumab or Monotherapy in Untreated Melano­
ma. New England Journal of Medicine 373(1): 23-34. https://doi. 
org/10.1056/NEJMoa1504030 [New England journal of medicine]
■ Liu KG, Gupta S, Goel S (2017) Immunotherapy: Incorporation in 
the Evolving Paradigm of Renal Cancer Management and Future 
Prospects. Oncotarget 8(10): 17313. https://doi.org/10.18632/onco- 
target.14388 [PMC]
■ Vodolazhskii DI, Kit OI, Mogushkova KhA, Pushkin AA, et al. (2017) 
Cancerous Testicular Antigens in Immunotherapy of Malignant Neo­
plasms. Sibirian Oncological Journal 16(2): 71-81. [in Russian]
■ ClinicalTrials.gov (2017) NCT01582672. An International Phase 
3 Randomized Trial of Autologous Dendritic Cell Immunotherapy 
(AGS-003) Plus Standard Treatment of Advanced Renal Cell Car­
cinoma (ADAPT). [An electronic resource] // ClinicalTrials.gov.
-  Access mode: https://clinicaltrials.gov/ct2/show/NCT01582672 
[accessed 10.10.2017]
■ Rini BI, Stenzl A, Zdrojowy R, Kogan M, et al. (2016) IMA901, 
a Multipeptide Ccancer Vaccine, Plus Sunitinib Versus Sunitinib 
Alone, as First-line Therapy for Advanced or Metastatic Renal Cell 
Carcinoma (IMPRINT): a Multicentre, Open-label, Randomised, 
Controlled, Phase 3 Trial. The Lancet Oncology 17(11): 1599-1611. 
https://doi.org/10.1016/S1470-2045(16)30408-9 [ScienceDirect]
■ Walter S, Weinschenk T, Stenzl A, Zdrojowy R, et al. (2012) Mul­
tipeptide Immune Response to Cancer Vaccine IMA901 After Sin­
gle-dose Cyclophosphamide Associates with Longer Patient Sur­
vival. Nature medicine 18(8): 1254-1261. https://doi.org/10.1038/ 
nm.2883 [Nature]
■ Rini B, Stenzl A, Zdrojowy R, Kogan M, et al. (2015) 17LBA Re­
sults from an Open-label, Randomized, Controlled Phase 3 Study 
Investigating IMA901 Multipeptide Cancer Vaccine in Patients 
Receiving Sunitinib as First-line Therapy for Advanced/metastatic
Research Result: Pharmacology and Clinical Pharmacology 4(1): 17-25 25
RCC. European Journal of Cancer 51:S718. https://doi.org/10.1016/ 
S0959-8049(16)31939-6 [EJC]
■ Griffiths RW, Gilham DE, Dangoor A, Ramani V, et al. (2 0 0 5 )  Ex­
pression of the 5T4 Oncofoetal Antigen in Renal Cell Carcinoma: 
a Potential Target for T-cell-based Immunotherapy. British Journal 
of Cancer 93(6): 670. https://doi.org/10.1038/sj.bjc.6602776 [PMC]
■ Amato RJ, Hawkins RE, Kaufman HL, Thompson JA, et al. (2010) 
Vaccination of Metastatic renal Cancer Patients with MVA-5T4: 
a Randomized, Double-blind, Placebo-controlled Phase III Study. 
Clinical Cancer Research 16(22): 1078-0432, CCR-10-2082. 
https://doi.org/10.1158/1078-0432.CCR-10-2082 [Aacrjournals]
■ Wittke S, Baxmann S, Fahlenkamp D, Kiessig ST (2016) Tumor 
Heterogeneity as a Rationale for a Multi-epitope Approach in an 
Autologous Renal Cell Cancer Tumor Vaccine. OncoTargets and 
Therapy 9: 523. https://doi.org/10.2147/OTT.S92182 [PMC]
■ May M, Brookman-MayBernd S, Gilfrich HC, et al. (2010) Ten-year 
Survival Analysis for Renal Carcinoma Patients Treated with an Au­
tologous Tumour Lysate Vaccine in an Adjuvant Setting. Cancer Im­
munology, Immunotherapy 59(5): 687-695. https://doi.org/10.1007/ 
s00262-009-0784-6 [Springer Link]
■ ClinicalTrials.gov (2017) A Phase I, Open Label, Dose Escalation 
and Cohort Expansion Study to Evaluate the Safety and Immune 
Response to Autologous Dendritic Cells Transduced With Ad-GM- 
CAIX in Patients With Metastatic Renal Cell Carcinoma. [An elec­
tronic resource] // ClinicalTrials.gov. -  Access mode: https://clini- 
caltrials.gov/ct2/show/NCT01826877 [accessed 10.10.2017]
■ ClinicalTrials.gov (2017) Phase II Study of PD-1 Blockade Alone or 
In Conjunction With the Dendritic Cell (DC) / Renal Cell Carcinoma 
(RCC) Fusion Cell Vaccination. [An electronic resource] // Clini- 
calTrials.gov. -  Access mode: https://clinicaltrials.gov/ct2/show/ 
NCT01441765 [accessed 10.10.2017]
■ ClinicalTrials.gov (2017) Study of Autologous Dendritic Cells (DC) 
Loaded With Autologous Tumor Lysate (DC-Vaccine) in Combination 
With CytokineInduced Killer Cell (CIK) in Patients With Renal Cell 
Cancer. [An electronic resource] // ClinicalTrials.gov. -  Access mode: 
https://clinicaltrials.gov/ct2/show/NCT00862303 [accessed 10.10.2017]
■ Perica K, Varela JC, Oelke M, Schneck J, et al. (2015) Adoptive 
T Cell Immunotherapy for Cancer. Rambam Maimonides Medical 
Journal 6(1). https://doi.org/10.5041/RMMJ.10179 [PMC]
■ Tang X, Liu T, Zang X, Liu H, et al. (2013) Adoptive Cellular Immu­
notherapy in Metastatic Renal Cell Carcinoma: a Systematic Review 
and Meta-analysis. PLoS One 8(5): e62847. https://doi.org/10.1371/ 
journal.pone.0062847 [PMC]
■ Combe P, Guillebon E, Thibault C, Granier C, et al. (2015) Trial 
Watch: Therapeutic Vaccines in Metastatic Renal Cell Carcino­
ma. Oncoimmunology 4(5): 100. https://doi.org/10.1080/216240 
2X.2014.1001236 [Taylor Francis online] [Full text]
■ Khunger M, Khunger M, Rakshit S, Pasupuleti V, et al. (2017) In­
cidence of Pneumonitis With Use of Programmed Death 1 and Pro­
grammed Death-ligand 1 Inhibitors in Non-small Cell Lung Cancer: 
A Systematic Review and Meta-analysis of Trials. Chest 152(2): 
271-281. https://doi.org/10.1016/j.chest.2017.04.177 [OvidInsights]
Contributors
■ Anton A. Pushkin, Junior researcher, Rostov Oncological Research Institute, e-mail: anton.a.pushkin@gmail.com. 
Contribution: collecting information, writing the article.
■ Yuriy E. Burda, PhD in Medicine, Supervisor of The Cellular Technologies Project, Innovative Centre Biruch
-  New Technologies Ltd. (EFKO Group R&D division); Associated Professor at the Department of Pharmacolo­
gy, Belgorod State National Research University, e-mail: yu.burda@brc.efko.ru ORCID: 0000-0002-1183-4436. 
Contribution: providing the concept, editing the article.
■ Aleksandr A. Sevast’yanov, Head of the Molecular-Cellular Technologies Directorate, Innovative Centre Biruch
-  New Technologies Ltd, e-mail: a.sevastyanov@brc.efko.ru. Contribution: collecting information.
■ Vladimir F. Kulikovskiy, Doctor of Medicine Full PhD, MD, Professor, Director of The Institute of Medicine, 
e-mail: kulikovskiy@bsu.edu.ru. Contribution: editing the article.
■ Svetlana Yu. Burda, student, Kursk State Medical University, e-mail: burdasvetlana@gmail.com. Contribution: 
collecting information, translation in English.
■ Polina A. Golubinskaya, a cell engineer, Cellular Technologies Project, Innovative Centre Biruch -  New Technologies 
Ltd. e-mail: p.golubinskaya@brc.efko.ru. Contribution: collecting information.
■ Alina K. Zvyagina, a cell engineer, Cellular Technologies Project, Innovative Centre Biruch -  New Technologies 
Ltd, e-mail: a.zvyagina@brc.efko.ru. Contribution: collecting information.
■ Natal’ya V. Kulyushina, a cell engineer, Cellular Technologies Project, Innovative Centre Biruch -  New Technologies 
Ltd., e-mail: n.kulyushina@brc.efko.ru. Contribution: collecting information.
